Compare H2O America (HTO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Neurocrine Biosciences Inc — how do they compare? H2O America trades at $62.3 (market cap $2.61B), while Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.3× H2O America's market cap, and H2O America pays a 2.83% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| HTO | NBIX | |
|---|---|---|
Market Cap | $2.61B | $16.46B |
Sector | Technology | Health |
52-Week High | $65.43 | $185.50 |
52-Week Low | $44.44 | $123.10 |
Enterprise Value | $4.40B | $16.48B |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $62.57, up 2.16% with bullish technical signals and strong analyst support. The stock shows solid fundamentals with 12.91% net margin and consistent earnings beats in recent quarters. Recent transformative acquisitions in Texas water utilities drive growth potential, though execution risks and share dilution from equity issuance present challenges. Technical indicators show bullish momentum with key resistance at $63 and support at $61.
Outlook remains positive with 83% analyst buy ratings and $69.50 consensus target offering 11% upside. Dividend sustainability and acquisition integration are key watchpoints. Risks include execution challenges from Quadvest deal and potential EPS dilution from recent 11M share issuance.
Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.
Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
